BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1405 related articles for article (PubMed ID: 19724909)

  • 1. Involvement of mTORC1 and mTORC2 in regulation of glioblastoma multiforme growth and motility.
    Gulati N; Karsy M; Albert L; Murali R; Jhanwar-Uniyal M
    Int J Oncol; 2009 Oct; 35(4):731-40. PubMed ID: 19724909
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PRR5, a novel component of mTOR complex 2, regulates platelet-derived growth factor receptor beta expression and signaling.
    Woo SY; Kim DH; Jun CB; Kim YM; Haar EV; Lee SI; Hegg JW; Bandhakavi S; Griffin TJ; Kim DH
    J Biol Chem; 2007 Aug; 282(35):25604-12. PubMed ID: 17599906
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Distinct signaling mechanisms of mTORC1 and mTORC2 in glioblastoma multiforme: a tale of two complexes.
    Jhanwar-Uniyal M; Gillick JL; Neil J; Tobias M; Thwing ZE; Murali R
    Adv Biol Regul; 2015 Jan; 57():64-74. PubMed ID: 25442674
    [TBL] [Abstract][Full Text] [Related]  

  • 4. ASCT2 silencing regulates mammalian target-of-rapamycin growth and survival signaling in human hepatoma cells.
    Fuchs BC; Finger RE; Onan MC; Bode BP
    Am J Physiol Cell Physiol; 2007 Jul; 293(1):C55-63. PubMed ID: 17329400
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Regulation of mTORC1 and mTORC2 complex assembly by phosphatidic acid: competition with rapamycin.
    Toschi A; Lee E; Xu L; Garcia A; Gadir N; Foster DA
    Mol Cell Biol; 2009 Mar; 29(6):1411-20. PubMed ID: 19114562
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rapamycin derivatives reduce mTORC2 signaling and inhibit AKT activation in AML.
    Zeng Z; Sarbassov dos D; Samudio IJ; Yee KW; Munsell MF; Ellen Jackson C; Giles FJ; Sabatini DM; Andreeff M; Konopleva M
    Blood; 2007 Apr; 109(8):3509-12. PubMed ID: 17179228
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibition of PI3K-Akt-mTOR signaling in glioblastoma by mTORC1/2 inhibitors.
    Fan QW; Weiss WA
    Methods Mol Biol; 2012; 821():349-59. PubMed ID: 22125077
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synergistic Effects between mTOR Complex 1/2 and Glycolysis Inhibitors in Non-Small-Cell Lung Carcinoma Cells.
    Jiang S; Zou Z; Nie P; Wen R; Xiao Y; Tang J
    PLoS One; 2015; 10(7):e0132880. PubMed ID: 26176608
    [TBL] [Abstract][Full Text] [Related]  

  • 9. mTORC1-activated S6K1 phosphorylates Rictor on threonine 1135 and regulates mTORC2 signaling.
    Julien LA; Carriere A; Moreau J; Roux PP
    Mol Cell Biol; 2010 Feb; 30(4):908-21. PubMed ID: 19995915
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Receptor-recognized α₂-macroglobulin binds to cell surface-associated GRP78 and activates mTORC1 and mTORC2 signaling in prostate cancer cells.
    Misra UK; Pizzo SV
    PLoS One; 2012; 7(12):e51735. PubMed ID: 23272152
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dual PI3K/mTOR Inhibitors Induce Rapid Overactivation of the MEK/ERK Pathway in Human Pancreatic Cancer Cells through Suppression of mTORC2.
    Soares HP; Ming M; Mellon M; Young SH; Han L; Sinnet-Smith J; Rozengurt E
    Mol Cancer Ther; 2015 Apr; 14(4):1014-23. PubMed ID: 25673820
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting cancer stem cells in glioblastoma multiforme using mTOR inhibitors and the differentiating agent all-trans retinoic acid.
    Friedman MD; Jeevan DS; Tobias M; Murali R; Jhanwar-Uniyal M
    Oncol Rep; 2013 Oct; 30(4):1645-50. PubMed ID: 23877261
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Enhancing mammalian target of rapamycin (mTOR)-targeted cancer therapy by preventing mTOR/raptor inhibition-initiated, mTOR/rictor-independent Akt activation.
    Wang X; Yue P; Kim YA; Fu H; Khuri FR; Sun SY
    Cancer Res; 2008 Sep; 68(18):7409-18. PubMed ID: 18794129
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Discrete signaling mechanisms of mTORC1 and mTORC2: Connected yet apart in cellular and molecular aspects.
    Jhanwar-Uniyal M; Amin AG; Cooper JB; Das K; Schmidt MH; Murali R
    Adv Biol Regul; 2017 May; 64():39-48. PubMed ID: 28189457
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Upregulation of mTORC2 activation by the selective agonist of EPAC, 8-CPT-2Me-cAMP, in prostate cancer cells: assembly of a multiprotein signaling complex.
    Misra UK; Pizzo SV
    J Cell Biochem; 2012 May; 113(5):1488-500. PubMed ID: 22173835
    [TBL] [Abstract][Full Text] [Related]  

  • 16. mTORC1 and mTORC2 regulate insulin secretion through Akt in INS-1 cells.
    Le Bacquer O; Queniat G; Gmyr V; Kerr-Conte J; Lefebvre B; Pattou F
    J Endocrinol; 2013 Jan; 216(1):21-9. PubMed ID: 23092880
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Increased AKT S473 phosphorylation after mTORC1 inhibition is rictor dependent and does not predict tumor cell response to PI3K/mTOR inhibition.
    Breuleux M; Klopfenstein M; Stephan C; Doughty CA; Barys L; Maira SM; Kwiatkowski D; Lane HA
    Mol Cancer Ther; 2009 Apr; 8(4):742-53. PubMed ID: 19372546
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rapamycin attenuates BAFF-extended proliferation and survival via disruption of mTORC1/2 signaling in normal and neoplastic B-lymphoid cells.
    Zeng Q; Qin S; Zhang H; Liu B; Qin J; Wang X; Zhang R; Liu C; Dong X; Zhang S; Huang S; Chen L
    J Cell Physiol; 2018 Jan; 233(1):516-529. PubMed ID: 28300280
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CD40-induced signaling in human endothelial cells results in mTORC2- and Akt-dependent expression of vascular endothelial growth factor in vitro and in vivo.
    Dormond O; Contreras AG; Meijer E; Datta D; Flynn E; Pal S; Briscoe DM
    J Immunol; 2008 Dec; 181(11):8088-95. PubMed ID: 19018001
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rapamycin inhibits cytoskeleton reorganization and cell motility by suppressing RhoA expression and activity.
    Liu L; Luo Y; Chen L; Shen T; Xu B; Chen W; Zhou H; Han X; Huang S
    J Biol Chem; 2010 Dec; 285(49):38362-73. PubMed ID: 20937815
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 71.